SIOPEN

  • International Society of Paediatric Oncology Europe Neuroblastoma

Long-term antibody Infusion study

This is an early-phase clinical trial for patients with refractory (not responding to initial treatment) or relapsed neuroblastoma. Patients will receive a combination of anti-GD2 antibody (ch14.18/CHO) given as a prolonged continuous infusion and IL2 (aldesleukin). The study is open at a limited number of centres in Austria, Australia, France, Germany, Ireland, Israel, Italy, Spain and the United Kingdom.

More information (Cancer Research UK)

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information

SIOPEN

SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.